Table 5. Comparisons of the expression levels of Bcl-2, Caspase-3 and Caspase-8 among different subgroups based on the application of different intervention approaches.
| Protein | Group | SOD treatment | Group | anti-TNFR treatment | Group | NF-kB inhibitor treatment |
|---|---|---|---|---|---|---|
| Bcl-2 | ||||||
| A | 0.291 ± 0.056 | A | 0.324 ± 0.045 | A | 0.350 ± 0.044 | |
| B | 0.147 ± 0.034* | C | 0.264 ± 0.035* | C | 0.265 ± 0.040* | |
| C | 0.245 ± 0.034** | D | 0.160 ± 0.033** | E | 0.165 ± 0.031** | |
| Caspase-3 | ||||||
| A | 0.198 ± 0.024 | A | 0.231 ± 0.050 | A | 0.231 ± 0.041 | |
| B | 0.134 ± 0.030* | C | 0.224 ± 0.042 | C | 0.221 ± 0.038 | |
| C | 0.200 ± 0.037** | D | 0.154 ± 0.032** | E | 0.143 ± 0.030** | |
| Caspase-8 | ||||||
| A | 0.234 ± 0.050 | A | 0.238 ± 0.056 | A | 0.242 ± 0.042 | |
| B | 0.153 ± 0.034* | C | 0.230 ± 0.043 | C | 0.195 ± 0.034* | |
| C | 0.213 ± 0.042** | D | 0.182 ± 0.040** | E | 0.162 ± 0.027** |
Note: A, control group; B, SOD group; C, TNFR group; D, anti-TNFR group; E, NF-kB inhibitor group. *P < 0.05 when compared with group A; **P < 0.05 when compared with group B or group C.